Bio-Rad Laboratories, Inc. (BIO-B) Stock Price & Analysis
Bio-Rad Laboratories, Inc. (BIO-B) rose 0.00% to USD 309.37 as of July 25, 2026 at 05:33 UTC, according to Nexqual real-time market data.
BIO-B last closed at USD 309.37; the session ranged USD 309.37–309.37 on volume of 3 shares. Market capitalization is $8.28B, with a 52-week range of USD 244.54–321.12 (NYQ). Source: Nexqual, July 25, 2026 at 05:33 UTC.
Key Statistics (as of July 25, 2026 at 05:33 UTC)
| Price | USD 309.37 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 309.37 |
| Open | USD 309.37 |
| Day Range | USD 309.37 – 309.37 |
| 52-Week Range | USD 244.54 – 321.12 |
| Volume | 3 shares |
| Market Cap | $8.28B |
| Exchange | NYQ |
Technical Analysis (BIO-B)
Nexqual's technical model rates BIO-B "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 05:33 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.96 (neutral) |
| vs SMA50 | Above (USD 295.86) |
| MACD | 3.88 (positive) |
Analyst Ratings (BIO-B)
Wall Street analysts rate BIO-B "None", per Nexqual as of July 25, 2026 at 05:33 UTC.
| Consensus Rating | None |
|---|
Earnings (BIO-B)
| Revenue Estimate | $623.99M |
|---|
Source: Nexqual, July 25, 2026 at 05:33 UTC.
Financials & Fundamentals (BIO-B)
| Total Revenue | $2.59B |
|---|---|
| Revenue Growth (YoY) | +1.10% |
| Gross Margin | +52.01% |
| Operating Margin | +5.76% |
| Profit Margin | +6.52% |
| ROE | +2.50% |
| Debt / Equity | 20.12 |
| Current Ratio | 3.21 |
| Total Cash | $1.56B |
| Total Debt | $1.38B |
| Free Cash Flow | $229.76M |
Source: Nexqual, July 25, 2026 at 05:33 UTC.
Financial Health Score (BIO-B)
Nexqual rates Bio-Rad Laboratories, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:33 UTC.
| Growth | Mixed — Revenue +0.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 6% |
| Balance Sheet | Strong — $1.56B cash vs $1.38B debt, net cash position |
| Cash Flow | Solid — FCF $230M, 9% margin |
| Efficiency | Weak — ROE 2%, ROA 1.8% |
Ownership (BIO-B)
| Insider Ownership | +98.23% |
|---|---|
| Institutional Ownership | +0.08% |
| Shares Outstanding | 5.06M |
| Float | 20.91M |
| Short % of Float | +0.01% |
Source: Nexqual, July 25, 2026 at 05:33 UTC.
Leadership (BIO-B)
Bio-Rad Laboratories, Inc. is led by Norman D. Schwartz (age 75), Chairman & CEO, per Nexqual as of July 25, 2026 at 05:33 UTC.
| Chairman & CEO | Norman D. Schwartz (age 75) |
|---|---|
| President & COO | Jonathan P. DiVincenzo (age 59) |
| Executive VP & CFO | Roop K. Lakkaraju (age 54) |
| Executive VP & President of Life Science Group | James J. Barry (age 47) |
| Executive Vice President of Global Commercial Operations | Rajat Mehta (age 46) |
From Bio-Rad Laboratories, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
- It operates through two segments, Life Science and Clinical Diagnostics.
- The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications.
- This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MKC-V | McCormick & Company, Incorporat | USD 50.61 | ▼ 1.92% |
| TAP-A | Molson Coors Beverage Company | USD 39.51 | ▼ 3.63% |
| WSO-B | Watsco, Inc. | USD 381.7 | ▼ 0.86% |
| GEF-B | Greif, Inc. Corporation | USD 96.35 | ▲ 3.19% |
| LEN-B | Lennar Corporation | USD 82.92 | ▲ 2.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:33 UTC. This page is informational and not investment advice.